Acrux Share Price and Company Fundamentals
Last traded: Yesterday at 11:23 PM
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain associated with chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
4.67
Dividend yield
-
Beta
0.95
Market cap
$5.75M
Enterprise value
$8.50M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.acrux.com.au |
| Mailing address | 103-113, Stanley Street West Melbourne VIC 3003 Australia |
| Phone / Fax | 61 3 8379 0100 / 61 3 8379 0101 |
Dividends
More: Acrux Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Acrux paid $- dividend and the ex-dividend date was 18 Aug 2015.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.ACR dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Acrux.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. John Warmbrunn | MD, CEO & Director | ||
| Ms. Joanna Johnson B.E., BEc, ICAA | CFO & Company Secretary | ||
| Ms. Felicia Colagrande B.Sc., BSc (Hons), M.B.A. | Product Development & Technical Affairs Director | ||
| Mr. Mark Hyman | Project & Technical Development Director |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-355.05%
Return on assets
-69.27%
Return on equity
-276.58%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Acrux is 5.75M and its enterprise value is 8.50M. The enterprise value to revenue ratio of ACR is 7.14. The enterprise value to EBITDA ratio of ACR is -0.97.
The ACR's stocks Beta value is 0.95 making it 5% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Acrux (ACR)
Acrux (ASX:ACR) Frequently Asked Questions
1. What is Acrux's Stock Symbol?
Acrux trades on ASX under the ticker symbol "ACR".
2. What is Acrux's stock price today?
One share of ACR stock can currently be purchased for approximately $0.014.
3. How can I contact Acrux?
Acrux's mailing address is 103-113, Stanley Street West Melbourne VIC 3003 Australia. The company can be reached via phone at 61 3 8379 0100.
4. What is Acrux's official website?
The official website of Acrux is https://www.acrux.com.au.